This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

EfficacyEfficacyBosulif EfficacyBFORE StudyBFORE 5-year dataBYOND StudyStudy 200Study 200 extensionSafetyDosingSupport & ResourcesSupport & ResourcesResource overviewMaterialsVideosPatient SupportGuidelinesCML Digital ChecklistCML Patient Case StudiesCML Monitoring Video Series New Challenges Video

The content of this website has been produced in line with the BOSULIF® (bosutinib) Summary of Product Characteristics for Great Britain and Northern Ireland. For BOSULIF® (bosutinib) Prescribing Information Click here. Adverse event reporting information can be found at the bottom of the page.

Rapid and Deep Responses in First-line1-3

Data in newly-diagnosed adult CML patients from the BFORE study

Compared with imatinib, BOSULIF offers:1-3

  • Superior MMR and CCyR at 12 months (48 weeks) 
  • Quicker reduction in BCR-ABL1 transcripts
  • Deeper molecular responses​​​​​

Adapted from Cortes JE, et al. 20182 and Clark RE, et al, 2018.3

BOSULIF: Confidence to achieve meaningful clinical outcomes​​​​​​​

*MMR (≤ 0.1% BCR-ABL1 transcripts on the international scale with ≥ 3000 ABL1 assessed).
Adjusted for Sokal risk group (low, intermediate, high) and geographical region at time of random assignment. 95% CIs for ORs based on asymptotic Wald confidence limits.
p-value based on a Cochran–Mantel–Haenszel test for general association between treatment and response with stratification by Sokal risk group (low, intermediate, high) and region as determined at time of random assignment.
§MR4, ≤ 0.01% BCR-ABL1 transcripts on the international scale with ≥ 9800 ABL1 assessed; MR4.5, ≤ 0.0032% BCR-ABL1 transcripts on the international scale with ≥ 30,990 ABL1 assessed.

Review ELN Guidelines

Compare 2013 guidelines to those published in 2020

Download hereLoading

BFORE 5 year first-line data

Review the long-term efficacy and safety data for adult patients with newly diagnosed CML

Explore more Loading

ABL, Abelson; BCR, breakpoint cluster region; CCyR, complete cytogenetic response; CI, confidence interval; CML, chronic myeloid leukaemia; ELN; European LeukemiaNet, mITT, modified intention-to-treat; MMR, major molecular response; MR, molecular response; OR, odds ratio.​​​​​​​

References:

BOSULIF Summary of Product Characteristics for Great Britain click here. BOSULIF Summary of Product Characteristics for Northern Ireland click here.    Cortes JE, et al. J Clin Oncol 2018;36:231–237.Clark RE, et al. Presented at the British Society for Haematology (BSH) Annual Meeting, 2018; Oral presentation BSH18-OR-004
PP-BOS-GBR-1609. June 2022

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​